US firm Vical will carry out a phase 1 clinical trial of its Vaxfectin-formulated DNA vaccine for A/H1N1 pandemic swine flu influenza for the US Navy.

The funds will be provided by the navy through the Henry M Jackson Foundation for the Advancement of Military Medicine.

The investigational new drug application describing the trial design was approved by the US Food and Drug Administration in 2009.

According to the company, the navy funding builds on the success of our H5N1 vaccine, expand the safety and immunogenicity database for Vaxfectin-formulated vaccines in humans, and open the door to broader collaborations with the US Government.